Vergelijking
CagriSema vs. Mazdutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
2259884-03-0
Molecuulmassa
geen gegevens
4790 g/mol
Halfwaardetijd
geen gegevens
132 h
Sequentie
geen gegevens
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteWerkingsmechanisme
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
1
4
waarvan bij mensen
1
4
Geregistreerde effecten
2
4
Openstaande tegenstrijdigheden
0
0
Gedocumenteerde bijwerkingen
1
0
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between CagriSema and Mazdutide?
- CagriSema is classified as "Metabool", while Mazdutide is classified as "Metabool". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Mazdutide?
- The highest available evidence level is "Humane RCT" for CagriSema and "Humane RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Mazdutide in Germany and the United States?
- Duitsland: CagriSema — Niet goedgekeurd, Mazdutide — Alleen onderzoek. Verenigde Staten: CagriSema — Niet goedgekeurd, Mazdutide — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.